Literature DB >> 31155235

Tracing Oncogene Rearrangements in the Mutational History of Lung Adenocarcinoma.

Jake June-Koo Lee1, Seongyeol Park2, Hansol Park3, Sehui Kim4, Jongkeun Lee5, Junehawk Lee6, Jeonghwan Youk2, Kijong Yi2, Yohan An3, In Kyu Park7, Chang Hyun Kang7, Doo Hyun Chung4, Tae Min Kim8, Yoon Kyung Jeon9, Dongwan Hong5, Peter J Park10, Young Seok Ju11, Young Tae Kim12.   

Abstract

Mutational processes giving rise to lung adenocarcinomas (LADCs) in non-smokers remain elusive. We analyzed 138 LADC whole genomes, including 83 cases with minimal contribution of smoking-associated mutational signature. Genomic rearrangements were not correlated with smoking-associated mutations and frequently served as driver events of smoking-signature-low LADCs. Complex genomic rearrangements, including chromothripsis and chromoplexy, generated 74% of known fusion oncogenes, including EML4-ALK, CD74-ROS1, and KIF5B-RET. Unlike other collateral rearrangements, these fusion-oncogene-associated rearrangements were frequently copy-number-balanced, representing a genomic signature of early oncogenesis. Analysis of mutation timing revealed that fusions and point mutations of canonical oncogenes were often acquired in the early decades of life. During a long latency, cancer-related genes were disrupted or amplified by complex rearrangements. The genomic landscape was different between subgroups-EGFR-mutant LADCs had frequent whole-genome duplications with p53 mutations, whereas fusion-oncogene-driven LADCs had frequent SETD2 mutations. Our study highlights LADC oncogenesis driven by endogenous mutational processes.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  SETD2; balanced rearrangement; chromoplexy; chromothripsis; complex genomic rearrangement; fusion oncogene; lung adenocarcinoma; p53; tumor initiation; whole-genome duplication

Year:  2019        PMID: 31155235     DOI: 10.1016/j.cell.2019.05.013

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  62 in total

1.  Stereotactic ablative radiotherapy for early-stage central lung tumors: status, challenges, and future considerations.

Authors:  Ming Li; Cheng Zhan
Journal:  Ann Transl Med       Date:  2019-09

2.  Testing the suitability of neuroanatomical tracing method in human fetuses with long years of postmortem delay.

Authors:  Nail Can Öztürk; Turan Koç
Journal:  Surg Radiol Anat       Date:  2022-04-27       Impact factor: 1.246

Review 3.  Histone lysine methyltransferases in biology and disease.

Authors:  Dylan Husmann; Or Gozani
Journal:  Nat Struct Mol Biol       Date:  2019-10-03       Impact factor: 15.369

Review 4.  Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy.

Authors:  Ferdinandos Skoulidis; John V Heymach
Journal:  Nat Rev Cancer       Date:  2019-08-12       Impact factor: 60.716

Review 5.  Mechanistic origins of diverse genome rearrangements in cancer.

Authors:  Rashmi Dahiya; Qing Hu; Peter Ly
Journal:  Semin Cell Dev Biol       Date:  2021-04-03       Impact factor: 7.727

6.  Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes.

Authors:  Stefan C Dentro; Ignaty Leshchiner; Kerstin Haase; Maxime Tarabichi; Jeff Wintersinger; Amit G Deshwar; Kaixian Yu; Yulia Rubanova; Geoff Macintyre; Jonas Demeulemeester; Ignacio Vázquez-García; Kortine Kleinheinz; Dimitri G Livitz; Salem Malikic; Nilgun Donmez; Subhajit Sengupta; Pavana Anur; Clemency Jolly; Marek Cmero; Daniel Rosebrock; Steven E Schumacher; Yu Fan; Matthew Fittall; Ruben M Drews; Xiaotong Yao; Thomas B K Watkins; Juhee Lee; Matthias Schlesner; Hongtu Zhu; David J Adams; Nicholas McGranahan; Charles Swanton; Gad Getz; Paul C Boutros; Marcin Imielinski; Rameen Beroukhim; S Cenk Sahinalp; Yuan Ji; Martin Peifer; Inigo Martincorena; Florian Markowetz; Ville Mustonen; Ke Yuan; Moritz Gerstung; Paul T Spellman; Wenyi Wang; Quaid D Morris; David C Wedge; Peter Van Loo
Journal:  Cell       Date:  2021-04-07       Impact factor: 41.582

Review 7.  Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment.

Authors:  Martyna Filipska; Rafael Rosell
Journal:  Mol Oncol       Date:  2021-05-26       Impact factor: 6.603

8.  Genomic Characterization of Concurrent Alterations in Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Mutations.

Authors:  Antonio Passaro; Ilaria Attili; Alessandra Rappa; Davide Vacirca; Alberto Ranghiero; Caterina Fumagalli; Juliana Guarize; Lorenzo Spaggiari; Filippo de Marinis; Massimo Barberis; Elena Guerini-Rocco
Journal:  Cancers (Basel)       Date:  2021-04-30       Impact factor: 6.639

9.  Unraveling Ewing Sarcoma Tumorigenesis Originating from Patient-Derived Mesenchymal Stem Cells.

Authors:  Didier Surdez; Erika Brunet; Anna Sole; Sandrine Grossetête; Maxime Heintzé; Loelia Babin; Sakina Zaïdi; Patrick Revy; Benjamin Renouf; Anne De Cian; Carine Giovannangeli; Cécile Pierre-Eugène; Isabelle Janoueix-Lerosey; Lucile Couronné; Sophie Kaltenbach; Mark Tomishima; Maria Jasin; Thomas G P Grünewald; Olivier Delattre
Journal:  Cancer Res       Date:  2021-08-02       Impact factor: 12.701

10.  Revealing the impact of structural variants in multiple myeloma.

Authors:  Ola Landgren; Francesco Maura; Even H Rustad; Venkata D Yellapantula; Dominik Glodzik; Kylee H Maclachlan; Benjamin Diamond; Eileen M Boyle; Cody Ashby; Patrick Blaney; Gunes Gundem; Malin Hultcrantz; Daniel Leongamornlert; Nicos Angelopoulos; Luca Agnelli; Daniel Auclair; Yanming Zhang; Ahmet Dogan; Niccolò Bolli; Elli Papaemmanuil; Kenneth C Anderson; Philippe Moreau; Hervé Avet-Loiseau; Nikhil C Munshi; Jonathan J Keats; Peter J Campbell; Gareth J Morgan
Journal:  Blood Cancer Discov       Date:  2020-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.